Data | AUM totale | NAV | ISIN |
21/03/05 | 35 307 160€ | 114.786€ | IE00BF4Q4063 |
Data | AUM totale | NAV | Niveau de l’indice de référence | Valuta | ISIN | Ticker Bloomberg |
21/03/05 | 35 307 160€ | 114.786€ | 100.79 | EUR | IE00BF4Q4063 |
- Introduzione
- Caratteristiche
- Esposizione
- Performances
- Paniere
L’Ossiam World ESG Machine Learning UCITS ETF si pone l’obiettivo di raggiungere i rendimenti netti totali di un gruppo selezionato di azioni dei mercati sviluppati globali, grazie all’utilizzo di un algoritmo di machine learning che classifica le aziende in base ai fattori ESG (Environment, Social Responsability, Governance) e il loro potenziale in termini finanziari, calcolati tramite l’analisi dei dati. La selezione di aziende viene poi migliorata con il tempo, in quanto l’algoritmo apprende dai dati.
Forma giuridica e nome |
ICAV - Ossiam IRL ICAV |
Domicilio |
Irlanda |
Tipo di fondo |
UCITS ETF gestita attivamente |
Data di lancio |
26/11/2018 |
TER |
0.65% |
Valuta del fondo |
USD |
Valuta della classe |
EUR |
Copertura valutaria |
no |
Politica dei dividendi |
capitalizzazione |
Investimento minimo sur mercato secondario |
1 azione |
Metodo di replica |
fisico |
Società di gestione |
Ossiam |
Banca depositaria |
The Bank of New York Mellon SA/NV, Dublin Branch |
Agente amministrativo e Conservatore del registro |
BNY Mellon Fund Services (Ireland) Designated Activity |
Società di revisione |
Deloitte |
ISIN code |
IE00BF4Q4063 |
Bloomberg code |
OWLE IM |
Reuters code |
OWLE.MI |
Indice di riferimento | ISIN |
Indice di riferimento | ISIN | RIC Reuters | Ticker Bloomberg | Metodologia |
Fonte: Ossiam - Elaborazione Ossiam
Fonte: Ossiam - Elaborazione Ossiam
![]() |
Avvertenze |
Ossiam IRL (the ICAV) is organized as an Irish collective asset-management vehicle constituted as an umbrella fund with segregated liability between sub-funds with registered number C173953 authorized by the Central Bank of Ireland pursuant to the UCITS Regulations. The ICAV has appointed Ossiam as its management company, responsible for the investment management, administration and distribution of the ICAV.
Ossiam, a subsidiary of Natixis Investment Managers, is a French asset manager authorized by the Autorité des Marchés Financiers (Agreement No. GP-10000016). Although information contained herein is from sources believed to be reliable, Ossiam makes no representation or warranty regarding the accuracy of any information of which it is not the source. The information presented in this page is based on market data at a given moment and may change from time to time. The risks associated with the Fund are detailed in the « Investment Risks » section of the Supplement, available in English on www.ossiam.com. Investments decision should only be made on the basis of the Prospectus and Supplement. Accordingly, if investors have any questions about the registration or authorization of the sub-fund referenced on this page, they should contact the Management Company or Investment Manager for further information. Any investment in or distribution of the sub-fund referenced herein would only be possible if it was in compliance with all applicable laws and regulations, including, but not limited to obtaining any required registrations.
Fonte: Ossiam / Bloomberg - Elaborazione Ossiam - I RENDIMENTI PASSATI NON SONO INDICATIVI DI QUELLI FUTURI
![]() |
Avvertenze |
Ossiam IRL (the ICAV) is organized as an Irish collective asset-management vehicle constituted as an umbrella fund with segregated liability between sub-funds with registered number C173953 authorized by the Central Bank of Ireland pursuant to the UCITS Regulations. The ICAV has appointed Ossiam as its management company, responsible for the investment management, administration and distribution of the ICAV.
Ossiam, a subsidiary of Natixis Investment Managers, is a French asset manager authorized by the Autorité des Marchés Financiers (Agreement No. GP-10000016). Although information contained herein is from sources believed to be reliable, Ossiam makes no representation or warranty regarding the accuracy of any information of which it is not the source. The information presented in this page is based on market data at a given moment and may change from time to time. The risks associated with the Fund are detailed in the « Investment Risks » section of the Supplement, available in English on www.ossiam.com. Investments decision should only be made on the basis of the Prospectus and Supplement. Accordingly, if investors have any questions about the registration or authorization of the sub-fund referenced on this page, they should contact the Management Company or Investment Manager for further information. Any investment in or distribution of the sub-fund referenced herein would only be possible if it was in compliance with all applicable laws and regulations, including, but not limited to obtaining any required registrations.
Per rispondere alle esigenze in materia di trasparenza, Ossiam pubblica la composizione dell’indice di referenza (con un ritardo di 10 giorni dovuto ai vincoli del fornitore dell’indice).
Nome | ISIN | Peso |
CLOROX COMPANY | US1890541097 | 3.28% |
KIMBERLY-CLARK CORP | US4943681035 | 2.96% |
GILEAD SCIENCES INC | US3755581036 | 2.76% |
Elisa OYJ | FI0009007884 | 2.01% |
LION CORP | JP3965400009 | 1.97% |
Essity AB | SE0009922164 | 1.83% |
SGS SA | CH0002497458 | 1.76% |
BioMerieux | FR0013280286 | 1.74% |
East Japan Railway Co | JP3783600004 | 1.73% |
Reckitt Benckiser Group PLC | GB00B24CGK77 | 1.73% |
Nome | ISIN | Peso |
CLOROX COMPANY | US1890541097 | 3.28% |
KIMBERLY-CLARK CORP | US4943681035 | 2.96% |
GILEAD SCIENCES INC | US3755581036 | 2.76% |
Elisa OYJ | FI0009007884 | 2.01% |
LION CORP | JP3965400009 | 1.97% |
Essity AB | SE0009922164 | 1.83% |
SGS SA | CH0002497458 | 1.76% |
BioMerieux | FR0013280286 | 1.74% |
East Japan Railway Co | JP3783600004 | 1.73% |
Reckitt Benckiser Group PLC | GB00B24CGK77 | 1.73% |
Source: Ossiam / Bloomberg - Calculation by Ossiam. Past performance is not a reliable indicator of future performance.
Equity Participation Rate (%) |
Dissemination in progress |